Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,769
archived clinical trials in
Migraine Headaches

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Decatur, GA
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Savannah, GA
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Savannah, GA
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Chicago, IL
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Ann Arbor, MI
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Kalamazoo, MI
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Springfield, MO
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Springfield, MO
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
St. Louis, MO
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Mount Vernon, NY
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Mount Vernon, NY
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Plainview, NY
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Plainview, NY
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Greensboro, NC
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Greensboro, NC
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
West Chester, OH
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
West Chester, OH
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Philadelphia, PA
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Wynnewood, PA
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Wynnewood, PA
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Memphis, TN
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Nashville, TN
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Dallas, TX
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Houston, TX
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
San Antonio, TX
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Alexandria, VA
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Alexandria, VA
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Virginia Beach, VA
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Seattle, WA
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Phoenix, AZ
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Irvine, CA
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Irvine, CA
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Newport Beach, CA
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Newport Beach, CA
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
San Francisco, CA
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Santa Monica, CA
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Santa Monica, CA
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Walnut Creek, CA
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Fairfield, CT
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Fairfield, CT
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Hallandale Beach, FL
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Hallandale Beach, FL
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Ocala, FL
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Ocala, FL
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Sunrise, FL
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Sunrise, FL
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Atlanta, GA
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Decatur, GA
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Savannah, GA
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Savannah, GA
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Crestview Hills, KY
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Crestview Hills, KY
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Ann Arbor, MI
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
St. Louis, MO
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Mount Vernon, NY
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Mount Vernon, NY
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Plainview, NY
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Plainview, NY
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Greensboro, NC
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Greensboro, NC
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Cincinnati, OH
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Cleveland, OH
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Philadelphia, PA
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Clarksville, TN
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Clarksville, TN
Click here to add this to my saved trials
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated:  2/2/2016
Clinical Research Facility
mi
from
Dallas, TX
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months
Status: Enrolling
Updated: 2/2/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials